Ligand Pharmaceuticals Incorporated LGND

301.52 2.48 0.83% as of 25 Sep
Market cap
$6.1B
P/E
30.1×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
30.01 0.00 23.79 0.00 27.85 0.00 2.13 12.54 144.13 0.00
P/S ratio
13.64 11.73 9.53 5.68 6.63 6.14 10.27 7.12 12.89 12.22
P/FCF ratio
60.02 21.84 0.00 9.96 23.24 20.56 0.00 9.42 19.20 32.34
P/Operating CF
79.63 68.83 155.09 20.83 57.97 1,869.86 (168.39) 54.99 58.09 71.13
P/B ratio
3.59 2.36 1.78 1.86 1.95 1.42 1.61 3.19 4.55 3.90
EV/Sales
12.48 10.17 8.27 5.04 6.56 6.38 6.70 6.58 13.19 13.15
EV/EBITDA
47.07 144.18 22.93 17.87 9.23 11.59 0.93 7.62 20.37 21.57
EV/FCF
54.93 18.94 (281.92) 8.84 22.98 21.36 (22.97) 8.70 19.64 34.80
Current Ratio
22.23 8.93 14.15 2.67 11.15 5.00 66.09 10.58 0.99 0.72
Net Debt/EBITDA
(4.36) (22.58) (3.59) (2.26) (0.11) 0.43 (0.49) (0.63) 0.46 1.53
Debt/Equity
0.44 0.00 0.00 0.15 0.39 0.63 0.83 1.13 0.61 0.71
ROE
13.47% (0.53%) 8.03% (4.70%) 7.47% (0.40%) 94.76% 29.84% 3.39% (0.57%)
ROA
9.95% (0.47%) 6.73% (3.24%) 4.30% (0.21%) 45.67% 14.84% 1.97% (0.30%)
ROIC
3.62% (2.50%) 1.41% 0.40% 8.10% 3.13% 149.54% 24.17% 9.64% 6.20%
Return on Tangible Assets
15.66% (1.30%) 22.08% (18.82%) 13.10% (0.72%) 56.50% 18.06% 530.91% 2.63%
Average Days of Receivables
83.12 92.70 109.27 65.17 138.49 131.81 126.69 81.28 66.21 49.24
Earnings Yield
3.33% (0.05%) 4.20% (3.00%) 3.59% (0.23%) 47.05% 7.97% 0.69% (0.09%)
Free Cash Flow Yield
1.67% 4.58% (0.31%) 10.04% 4.30% 4.86% (2.84%) 10.61% 5.21% 3.09%
Free Cash Flow per Share
2.50 4.64 (0.22) 7.12 4.24 3.18 (1.68) 8.66 4.44 1.98
Book value per Share
52.60 45.40 40.52 35.42 49.38 43.84 40.39 26.51 19.01 16.38
Free Cash Flow
48.31 84.84 (3.85) 120.02 70.53 51.49 (31.89) 183.17 93.47 41.19
EV/EBIT
81.61 0.00 90.98 325.52 15.25 27.82 1.00 10.10 27.33 32.66
Other line items

Show all line items

Columns are period end dates